Muqdad Hasan, MD
Endocrinology · Glen Ridge, NJNPI 1588156558
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 47 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $477, more than ten times the $14 reported in 2023.
Across 47 payments — averaging $19.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$195
- Lilly USA, LLC$134
- Amgen$110
- Sanofi-aventis U.S. LLC$80
- Corcept Therapeutics$73
- Medtronic$52
- plus $256 from 11 others
What the payments were for
- Food & beverage$900100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 11 | $195 |
| Lilly USA, LLC | 8 | $134 |
| Amgen | 6 | $110 |
| Sanofi-aventis U.S. LLC | 4 | $80 |
| Corcept Therapeutics | 3 | $73 |
| Medtronic | 2 | $52 |
| Ascensia Diabetes Care US Inc. | 2 | $38 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $33 |
| Bayer | 1 | $30 |
| Chiesi USA, Inc. | 1 | $28 |
| Sequel Med Tech, LLC | 1 | $23 |
| Alvogen Inc | 1 | $20 |
| Madrigal Pharmaceuticals | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Ionis Pharmaceuticals, Inc. | 1 | $17 |
| GSK | 1 | $14 |
| Embecta Corp. | 1 | $14 |
How this compares
Too few endocrinology providers in New Jerseyto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 318 | $485,292 |
| FarxigaDapagliflozin Propanediol | 201 | $227,501 |
| JardianceEmpagliflozin | 154 | $170,514 |
| MounjaroTirzepatide | 92 | $116,020 |
| TrulicityDulaglutide | 49 | $91,525 |
| JanuviaSitagliptin Phosphate | 44 | $48,953 |
| TradjentaLinagliptin | 36 | $40,339 |
| Tresiba Flextouch U-100Insulin Degludec | 51 | $26,677 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $23,210 |
| RybelsusSemaglutide | 11 | $17,528 |
| Humalog Kwikpen U-100Insulin Lispro | 67 | $15,450 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $11,773 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 17 | $10,743 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 88 | $9,443 |
| Bydureon BciseExenatide Microspheres | 11 | $8,953 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $195 | $506,691341 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $134 | $213,115166 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology providers in New Jerseyon file to place this against a meaningful peer group, so we don't.
Other endocrinology in Glen Ridge
- Oscar OrtizToms River$176K
- Merab JosephFair Lawn$99K
- Caryn BorgerFlorham Park$68K
- Rama ReddyBelleville$8K
- Brian FertigPiscataway$4K
- Samar BurshehVentnor City$4K
- Monika AkulaNeptune$4K
- Saleh KhaddashClifton$2K
- Andrew ParzialeMorristown$0
- Alexa YuenMorristown$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.